IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination
Open Access
- 6 March 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 360
Abstract
Vaccine adjuvants are traditionally used to augment and modulate the immunogenicity of vaccines, although in many cases it is unclear which specific molecules contribute to their stimulatory activity. We previously reported that both subcutaneous and intranasal administration of hydroxypropyl-β-cyclodextrin (HP-β-CD), a pharmaceutical excipient widely used to improve solubility, can act as an effective adjuvant for an influenza vaccine. However, the mechanisms by which mucosal immune pathway is critical for the intranasal adjuvant activity of HP-β-CD have not been fully delineated. Here, we show that intranasally administered HP-β-CD elicits a temporary release of IL-33 from alveolar epithelial type 2 cells in the lung; notably, IL-33 expression in these cells is not stimulated following the use of other vaccine adjuvants. The experiments using gene deficient mice suggested that IL-33/ST2 signaling is solely responsible for the adjuvant effect of HP-β-CD when it is administered intranasally. In contrast, the subcutaneous injection of HP-β-CD and the intranasal administration of alum, as a damage-associated molecular patterns (DAMPs)-inducing adjuvant, or cholera toxin, as a mucosal adjuvant, enhanced humoral immunity in an IL-33-independent manner, suggesting that the IL-33/ST2 pathway is unique to the adjuvanticity of intranasally administered HP-β-CD. Furthermore, the release of IL-33 was involved in the protective immunity against influenza virus infection which is induced by the intranasal administration of HP--CD-adjuvanted influenza split vaccine. In conclusion, our results suggest that an understanding of administration route- and tissue-specific immune responses is crucial for the design of unique vaccine adjuvants.Keywords
Funding Information
- Japan Science and Technology Agency (JPMJCR18H1)
- Japan Agency for Medical Research and Development (18ak0101068h)
This publication has 53 references indexed in Scilit:
- Long-term IL-33–producing epithelial progenitor cells in chronic obstructive lung diseaseJournal of Clinical Investigation, 2013
- Contribution of IL-33–activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected miceProceedings of the National Academy of Sciences, 2012
- Interleukin 33 as a Mechanically Responsive Cytokine Secreted by Living CellsJournal of Biological Chemistry, 2012
- IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin GProceedings of the National Academy of Sciences, 2012
- Novel vaccine development strategies for inducing mucosal immunityExpert Review of Vaccines, 2012
- Interleukin-1 Family Cytokines as Mucosal Vaccine Adjuvants for Induction of Protective Immunity against Influenza VirusJournal of Virology, 2010
- TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccinesNature, 2008
- Expression analysis of G Protein-Coupled Receptors in mouse macrophagesImmunome Research, 2008
- Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor SignalingScience, 2006
- A gene atlas of the mouse and human protein-encoding transcriptomesProceedings of the National Academy of Sciences, 2004